KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Total Liabilities (2016 - 2025)

AbbVie (ABBV) has disclosed Total Liabilities for 14 consecutive years, with $137.2 billion as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 4.12% to $137.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $137.2 billion through Dec 2025, up 4.12% year-over-year, with the annual reading at $137.2 billion for FY2025, 4.12% up from the prior year.
  • Total Liabilities for Q4 2025 was $137.2 billion at AbbVie, up from $136.5 billion in the prior quarter.
  • The five-year high for Total Liabilities was $140.8 billion in Q1 2024, with the low at $121.2 billion in Q1 2023.
  • Average Total Liabilities over 5 years is $131.2 billion, with a median of $133.2 billion recorded in 2024.
  • The sharpest move saw Total Liabilities surged 38.69% in 2021, then fell 7.38% in 2022.
  • Over 5 years, Total Liabilities stood at $131.1 billion in 2021, then fell by 7.3% to $121.5 billion in 2022, then grew by 2.3% to $124.3 billion in 2023, then grew by 6.02% to $131.8 billion in 2024, then increased by 4.12% to $137.2 billion in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $137.2 billion, $136.5 billion, and $137.3 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.